Showing posts with label Zika vaccine. Show all posts
Showing posts with label Zika vaccine. Show all posts

Saturday, February 10, 2018

Novel emerging infectious diseases in pregnancy

Last two decades have seen epidemics of several infectious diseases which were previously not so prevalent worldwide. Pregnant mothers are especially prone to many infections because of anatomical and physiological changes that accompany pregnancy. The immune tolerance to semiallogenic fetus is because of down regulation of immunity, which puts the pregnant women at high risk of other infectious diseases reports a paper published in May 2017 issue of Journal Obstetrics and Gynecology.

The world has seen epidemics of four major and other minor emerging infectious diseases in the last two decades such as severe acute respiratory syndrome, the 2009 H1N1 pandemic influenza, Ebola virus, and, most recently, the Zika virus. Each of this infection has unique implications in pregnant women that are distinctly different from general population.

Each of this infectious disease has different clinical course, complications and future implications when occurring in pregnant women and requires special technique and skills and coordination at national and international levels to contain the outbreak, some basic principles are common to all for diagnosing and limiting the spread of these diseases.

A number of epidemiological factors have contributed towards emergence and widespread occurrence of these infection in pregnant women like global travel, development of microbial resistance and barriers towards vaccinations in pregnant women in-spite of increasing evidence of distinct benefits to mother and fetus.

Although the general principles of disease containment are common to all, some disease specific measures for treatment and prevention of individual infections in pregnancy are:

SARS: During the severe acute respiratory syndrome (SARS) outbreak by coronavirus in 2003, standard non-pharmaceutical measures were applied, and global containment was achieved in 5 months.

Influenza: All pregnant women should get influenza vaccine every year as soon as it is available and should not wait for the unpredictable influenza season to start. It is safe in all the trimester. The rapid influenza tests currently available has low sensitivity resulting in many false negative results. Hence, to err on the side of safety it is always recommended to prescribe oseltamivir as precaution and is recommended both by Centers for Disease Control and Prevention (CDC) and the American College of Obstetricians and Gynecologists.

Ebola virus: Women are always at high risk for contracting Ebola during an epidemic as they are the primary caregivers to other infectious family members. Women who are pregnant with the virus during acute Ebola epidemic usually transmit virus to the fetus, leading to intrauterine fetal death, stillbirth, or neonatal death. Ebola virus is also excreted in breast milk.

They also transmit the virus to healthcare providers and caregivers during labor or abortion. Standard precaution including the use of personal protective equipment (PPE) during labor and delivery for protection against blood and body fluids should be used along with rigorous hand hygiene, appropriate waste, sharps and laundry management and cleaning and decontamination.

WHO states that women who get pregnant after having being recovered from Ebola infection are not infectious but standard precautions and use of PPE should be implemented all the time during handling such patients. 


Zika virus: Zika virus is a flavivirus that has potential for sexual and vector born transmission by Aedes (Stegomyia) species of mosquitoes. It was declared as a public health emergency by the World Health Organization from 2016. A pregnant woman is susceptible to Zika virus in all three trimesters. Maternal Zika infection is associated with a range of adverse neonatal complications, most important of which is microcephaly. Peripartum transmission is also known to occur.

In absence of antiviral vaccine, CDC recommends that all pregnant women should postpone their travel to Zika infected areas and those who are in such areas should avoid mosquito bite especially during the day.

Pregnant women with laboratory-confirmed Zika virus infection can be offered amniocentesis to test for Zika virus RNA by RT-PCR after 15 weeks of gestation.

Deliveries of mothers with positive Zika infection should take place at specialized center.   
No specific antiviral treatment is available.



Friday, August 5, 2016

First Zika virus vaccine enters phase 1 trials in US.


A healthy volunteer receives the NIAID Zika virus investigational DNA vaccine as part of an early-stage trial to test the vaccine’s safety and immunogenicity. This is the first administration of this vaccine in a human.
Credit: NIAID

The National Institute of Allergy and Infectious Diseases (NIAID) made a press announcement on August 3,2016 about its recent launch of phase I clinical trials for its newly developed DNA Zika vaccine.

Zika is rife in Puerto Rico, American Samoa, the US Virgin Islands, and Florida and United States department of defense(DoD) recently confirmed about 30 cases of Zika virus infection among troops. As per Florida Department of Health recent update there are 15 total number of non-travel related infections and 55 pregnant patients have been infected due to either local transmission, sex with an infected partner or travel.[1] A total of more than 6,400 Zika cases have been reported in the US and its territories.[2]  

The NIAID Zika virus vaccine is investigational and was developed in the beginning of this year. The vaccine contains bio-engineered, non-infective Zika virus plasmid that contains genetic code for protein of the Zika virus. When injected into our body by intramuscular route, the DNA quickly assemble into a virus like particle, that has lost its infecting capabilities. It incites an immune response in the host by making antibodies and T cells.

The DNA vaccine, is delivered on the site on skin via a short electrical pulse that propels the DNA, which seeks  human cells through a process called electroporation.

It is also known from the animal experiment that despite being genetically different, all strains of the Zika virus have identical surface antigen, thereby vaccine developed against one will be effective against others too. [3]

According to John Mascola, MD, director of NIAID’s Vaccine Research Center (VRC), “DNA or gene-based vaccines include antibodies, but they also can activate the cell-mediated immune response, which ultimately could yield strong and durable protection against disease.”

DNA vaccines are new in the vaccine armament and no other DNA vaccine has been approved by US.[4] But since they do not need to grow live virus, DNA vaccines have short development time.[5]
The vaccine will be tested in 80 healthy volunteer in Maryland and Atlanta. The volunteers will receive the first shot at the same time and then they are divided into 4 groups of 20 each receiving the subsequent shots at varying intervals to study which dosing schedule works best. All the participants will be closely monitored for 44 weeks of initial vaccine administration.[6]They will be tested to measure the immune response to the vaccine at 18 and 24 months after the initial dose.

Researchers have already tested the vaccines in animal studies and found them to be effective and safe. When monkeys were exposed to Zika virus 4 weeks after the second dose, they showed no clinical signs of infection nor the virus was found in the blood.[7]

Meanwhile, a similar vaccine developed by The Infectious Disease Research Centre (IDRC) and the Centre de recherche du CHU (Centre hospitalier de l’UniversitĂ©) at Laval University in Canada has also begin its phase 1 clinical trials.

The vaccine is temporarily named GLS-5700, and is manufactured by Inovio, based in Plymouth Meeting, Pennsylvania, and GeneOne Life Science, of Seoul, South Korea.

At this point of time around 18 countries around the world are competing each other to develop Zika virus vaccines including French pharmaceutical giant Sanofi SA and GlaxoSmithKline.

According to CDC Zika virus infection is a public health emergency because of its causation of congenital birth defects. Currently 61 countries and territories are infected with Zika virus and 12 countries have reported birth defects due to Zika.

If the phase 1 trial is successful, the vaccine will enter phase 2 trial in early part of 2017. But, even at this pace it will be another 2 years before it is commercially available.





[1] http://www.floridahealth.gov/newsroom/2016/08/080316-zika-update.html
[2] https://www.niaid.nih.gov/news/newsreleases/2016/Pages/Zika-Investigational-Vaccine.aspx
[3] https://www.niaid.nih.gov/news/newsreleases/2016/Pages/Zika-serotype.aspx#
[4] https://www.statnews.com/2016/08/03/nih-zika-vaccine-trial/?trendmd-shared=0
[5] http://fortune.com/2016/01/28/zika-virus-vaccine/
[6] http://www.contagionlive.com/news/niaid-zika-vaccine-enters-clinical-trial
[7] https://www.niaid.nih.gov/news/newsreleases/2016/Pages/3-Zika-Vaccine-Approaches.aspx#